{"@type": "dcat:Dataset", "accessLevel": "public", "accrualPeriodicity": "R/P3M", "bureauCode": ["009:20"], "contactPoint": {"@type": "vcard:Contact", "fn": "CDC-INFO", "hasEmail": "mailto:cdcinfo@cdc.gov"}, "description": "CDC is collaborating with Vitalant Research Institute, American Red Cross, and Westat Inc. to conduct a nationwide COVID-19 seroprevalence survey of blood donors. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies.\nInfection-induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection and refers to the percent of the population with anti-nucleocapsid antibodies.\nCombined infection-Induced and Vaccination-Induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection, COVID-19 vaccination, or both, and refers to the percent of the population that has anti-spike antibodies, anti-nucleocapsid antibodies, or both.\n\nThis link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022", "distribution": [{"@type": "dcat:Distribution", "downloadURL": "https://data.cdc.gov/api/v3/views/ar8q-3jhn/export.csv?accessType=DOWNLOAD", "mediaType": "text/csv"}, {"@type": "dcat:Distribution", "downloadURL": "https://data.cdc.gov/api/v3/views/ar8q-3jhn/query.json?accessType=DOWNLOAD", "mediaType": "application/json"}, {"@type": "dcat:Distribution", "downloadURL": "https://data.cdc.gov/api/v3/views/ar8q-3jhn/query.xml?accessType=DOWNLOAD", "mediaType": "application/xml"}], "identifier": "https://data.cdc.gov/api/views/ar8q-3jhn", "issued": "2022-11-04", "keyword": ["coronavirus", "covid", "covid-19", "covid19", "laboratory", "prevalence", "sars-cov", "seroprevalence", "serosurveys"], "landingPage": "https://data.cdc.gov/d/ar8q-3jhn", "license": "https://www.usa.gov/government-works", "modified": "2025-02-23", "programCode": ["009:020"], "publisher": {"@type": "org:Organization", "name": "Centers for Disease Control and Prevention"}, "spatial": "US", "temporal": "2022-01-01/2022-03-31", "theme": ["Laboratory Surveillance"], "title": "2022\u20132023 Nationwide Blood Donor Seroprevalence Survey Combined Infection- and Vaccination-Induced Seroprevalence Estimates"}